Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,208,688
  • Shares Outstanding, K 28,688
  • Annual Sales, $ 55,230 K
  • Annual Income, $ -164,080 K
  • EBIT $ -140 M
  • EBITDA $ -139 M
  • 60-Month Beta 1.16
  • Price/Sales 39.32
  • Price/Cash Flow N/A
  • Price/Book 17.17

Options Overview Details

View History
  • Implied Volatility 77.46% (-3.46%)
  • Historical Volatility 60.12%
  • IV Percentile 10%
  • IV Rank 2.24%
  • IV High 620.58% on 04/16/25
  • IV Low 65.00% on 08/28/25
  • Expected Move (DTE 13) 7.99 (10.38%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 1,556
  • Volume Avg (30-Day) 1,502
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 29,868
  • Open Int (30-Day) 31,677
  • Expected Range 69.00 to 84.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.84
  • Number of Estimates 7
  • High Estimate $-1.22
  • Low Estimate $-2.88
  • Prior Year $-3.30
  • Growth Rate Est. (year over year) +44.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.50 +23.18%
on 03/09/26
78.81 -2.31%
on 04/01/26
+8.63 (+12.62%)
since 03/02/26
3-Month
33.40 +130.51%
on 01/30/26
78.81 -2.31%
on 04/01/26
+33.57 (+77.31%)
since 01/02/26
52-Week
6.45 +1,093.64%
on 04/09/25
78.81 -2.31%
on 04/01/26
+67.10 (+678.86%)
since 04/02/25

Most Recent Stories

More News
NKTR SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

NKTR : 76.99 (+1.69%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR

NEW YORK , April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers....

NKTR : 76.99 (+1.69%)
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment Compliance

NKTR : 76.99 (+1.69%)
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Overstating Trial Integrity Prospects: Levi & Korsinsky

Time-Sensitive: Allegations Focus on Overstated REZOLVE-AA Trial Integrity and Prospects

NKTR : 76.99 (+1.69%)
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , March 31, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

NKTR : 76.99 (+1.69%)
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm

NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Nektar Therapeutics (NASDAQ: NKTR).

NKTR : 76.99 (+1.69%)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NEW YORK , March 31, 2026 /PRNewswire/ --

NKTR : 76.99 (+1.69%)
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

NKTR : 76.99 (+1.69%)
Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting

Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients

NKTR : 76.99 (+1.69%)
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , March 27, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

NKTR : 76.99 (+1.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 83.94
2nd Resistance Point 80.97
1st Resistance Point 78.98
Last Price 76.99
1st Support Level 74.02
2nd Support Level 71.05
3rd Support Level 69.06

See More

52-Week High 78.81
Last Price 76.99
Fibonacci 61.8% 51.17
Fibonacci 50% 42.63
Fibonacci 38.2% 34.09
52-Week Low 6.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.